EARLY CLINICAL-TRIAL OF A 1-DAY INTERMITTENT SCHEDULE FOR PENTAMETHYLMELAMINE

  • 1 January 1980
    • journal article
    • research article
    • Vol. 64  (8-9) , 993-995
Abstract
An early clinical trial of pentamethylmelamine (PMM), the monodemethylated derivative of hexamethylmelamine, was conducted in 22 adults with solid tumors. PMM was administered as a 2 h i.v. infusion every 4 wk at doses ranging from 40-2400 mg/m2. A combination of gastrointestinal and neurologic (CNS) toxicity was dose-limiting. Nausea and vomiting began at a dose of 265 mg/m2 and became progressively worse until it became life-threatening at doses of 1800-2400 mg/m2. CNS toxic effects consisting of agitation, confusion, drowsiness and loss of consciousness were first noted at a dose of 1200 mg/m2 and were seen in varying degrees at all higher dose levels. No other toxic effects were noteworthy except 2 instances of thrombocytopenia at low doses. No antitumor activity was observed. The further use of this schedule of administration for PMM is not recommended.

This publication has 0 references indexed in Scilit: